nach oben

Erschienen in:

10.02.2021 | Benigne Prostatahyperplasie | Zertifizierte Fortbildung

Medikamente und minimalinvasive Therapien

Benignes Prostatasyndrom: Lässt sich die Progression verhindern?

verfasst von: Dr. med. Johannes Salem, Prim. Univ.-Prof. Dr. Stephan Madersbacher, Prof. Dr. med. Martin C. Michel

Erschienen in: Uro-News | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Auszug

Die gutartige Vergrößerung der Prostata kann aufgrund ihrer Häufigkeit gut und gerne als Volkskrankheit bezeichnet werden. Ein zentrales Problem im medizinischen Umgang mit dem benignen Prostatasyndrom ist die Progression. Der folgende Artikel liefert eine Übersicht zur Inzidenz und zu den Risikofaktoren einer solchen Progression und beschreibt, inwiefern sie mithilfe von Medikamenten und minimalinvasiver Therapie aufgehalten werden kann. …

Madersbacher S et al. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019; 65: 458-64

Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008; 101 (Suppl 3): 17-21

Temml C et al. Prostate The natural history of lower urinary tract symptoms over five years. Eur Urol. 2003; 43: 374-80

Roehrborn CG et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999; 53: 473-80

Mehraban D. Clinical value of intravesical prostatic protrusion in the evaluation and management of prostatic and other lower urinary tract diseases. Asian J Urol. 2017; 4: 174-80

Sebastianelli A et al. Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus. 2018; 4: 25-7

Bajic P et al. Male bladder microbiome relates to lower urinary tract symptoms. Eur Urol Focus. 2020; 6: 376-82

Nickel JC et al. Chronic prostate inflammation predicts symptom progression in patients with chronic prostatitis/chronic pelvic pain. J Urol. 2017; 198: 122-8

Cartwright R et al. Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men. Eur Urol. 2014; 66: 752-68

10.

Michel MC et al. Lower urinary tract symptoms of benign prostatic obstruction - what's the long-term effectiveness of medical therapies? Eur Urol. 2001; 39 (Suppl. 3): 20-5

11.

McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349: 2387-98

12.

Roehrborn CG et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010; 57: 123-31

13.

D'Agate S et al. Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. Br J Clin Pharmacol. 2020; 86: 1585-99

14.

D'Agate S et al. Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH. World J Urol. 2020; 38: 463-72

15.

16.

Mynderse LA et al. Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Validation of Convective Thermal Energy Transfer and Characterization With Magnetic Resonance Imaging and 3-Dimensional Renderings. Urology. 2015; 86: 122-7

17.

McVary KT et al. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019; 126: 171-9

18.

McVary KT et al. Five year results of the prospective, randomized controlled trial of water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Late-Breaking Abstract. J Urol. 2020; 203: e1021

19.

Dixon CM et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016; 8: 207-16

20.

Darson M et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017; 9: 159-68

21.

Mollengarden D et al. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis. 21: 379-85

22.

Porpiglia F et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int. 2018; 122: 106-12

23.

Amparore D et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2020; https://doi.org/10.1038/s41391-020-00281-5

24.

Kadner G et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol. 2020; 38: 3235-44

25.

Abt D et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018; 361: k2338

26.

Ray AF et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UKROPE study). BJU Int. 2018; 122: 270-82

27.

Pisco JM et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol. 2016; 27: 1115-22

28.

Müllhaupt G et al. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. World J Urol. 2020; 38: 2595-9

Titel: Medikamente und minimalinvasive Therapien
Benignes Prostatasyndrom: Lässt sich die Progression verhindern?
verfasst von: Dr. med. Johannes Salem
Prim. Univ.-Prof. Dr. Stephan Madersbacher
Prof. Dr. med. Martin C. Michel
Publikationsdatum: 10.02.2021
Verlag: Springer Medizin
Schlagwörter: Benigne Prostatahyperplasie
Benigne Prostatahyperplasie
TURP
Erschienen in: Uro-News / Ausgabe 2/2021
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI: https://doi.org/10.1007/s00092-020-4503-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Generika: So riskant ist die Abhängigkeit von Asien

PCA: Wann mit der Hormontherapie beginnen?

Mikrohämaturie: Lohnt die erneute Abklärung?

DGU: neue Website für den Nachwuchs

Zweitlinientherapie nach Versagen einer NHA-Therapie

Transurethrale Prostataresektion - damals und heute